Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284930 | 0.93 | — | — | |
| SCHEMBL29263924 | 0.89 | HSD17B10 (0.67) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL19160682 | 0.79 | HSD17B10 (0.53) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL26728614 | 0.78 | HSD17B10 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL16312506 | 0.78 | HSD17B10 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7841853 | 0.78 | KMT2A (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL25623600 | 0.78 | HSD17B10 (0.56) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL13931708 | 0.78 | HSD17B10 (0.56) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL21076254 | 0.78 | HSD17B10 (0.56) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL20773628 | 0.77 | ACHE (0.47) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828283-B1 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE | UNIV MISSOURI (US) | 2018-04-18 | — | — | EP | claimed |
| US-9766252-B2 | Peptide with gold binding and EGFR receptor affinity and same attached to gold nanostructure | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2017-09-19 | — | — | US | claimed |
| US-20160041188-A1 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2016-02-11 | — | — | US | claimed |
| EP-2828283-A1 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE | The Curators Of The University Of Missouri (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142200-A1 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2013-09-26 | — | — | WO | claimed |
| EP-1390378-B1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF ARZNEIMITTEL (DE) | 2009-06-17 | — | — | EP | claimed |
| US-7396826-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2008-07-08 | — | — | US | claimed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | claimed |
| US-5830994-A | TETRAPEPTIDE; AMTIINFLAMMATORY AGENT, ANTIALLERGENS, COSMETICS; MELANOCTE STIMULATING HORMONE | INSTITUT EUROPEEN DE BIOLOGIE CELLULAIRE (FR) | 1998-11-03 | — | — | US | claimed |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| CN-107875401-B | Photo-crosslinking antibacterial nano-particles and preparation method and application thereof | 东南大学 | 2020-02-18 | — | — | CN | disclosed |
| WO-2020007234-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2020-01-09 | — | — | WO | disclosed |
| EP-1996734-B1 | METHOD AND APPARATUS FOR TARGET DETECTION USING ELECTRODE-BOUND VIRUSES | UNIV CALIFORNIA (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2828283-B1 | PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE | UNIV MISSOURI (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20050043269-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | 2005-02-24 | — | — | US | disclosed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6369098-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-.GAMMA. (PPAR.GAMMA.) AND/OR PPAR.ALPHA TREATMENT OF ENDOCRINE, SKIN, CARDIOVASCULAR, IMMUNOLOGICAL, NEUROLOGICAL, NEUROPSYCHIATRIC, NEOPLASTIC AND CHRONIC VIRAL DISEASES OF VARIOUS ORGANS | BETHESDA PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002013812-A1 | METHODS FOR TREATING INFLAMMATORY DISEASES | PERSHADSINGH HARRIHAR A (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001025226-A1 | DITHIOLANE DERIVATIVES | BETHESDA PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| US-5552085-A | CONTROLLING CORROSION ON THE METALLIC SURFACES OF DISTILLATION COLUMNS | NALCO CHEMICAL COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121979-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR1 | HSD17B10 141/4885KMT2A 3902/4885TARDBP 3224/4885 |
| US-20050043269-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | HSD17B10 169/4885KMT2A 3774/4885TARDBP 2874/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | HSD17B10 441/4885KMT2A 2780/4885TARDBP 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.